Ampersand Biosciences Competitors and Similar CompaniesClear all

Ampersand Biosciences's competitors and similar companies include Biomerica, Elucigene Diagnostics, Nittobo America and BBI Solutions.

	Ampersand Biosciences Ampersand Biosciences is a company that specializes in the development and manufacturing of antibodies, proteins, and reagents.	Biomerica Biomerica is a global biomedical company whose suite of diagnostic products are used for early detection of medical conditions and diseases.	Elucigene Diagnostics Elucigene Diagnostics is a company that designs, develops, and manufactures diagnostic assays.	Nittobo America Nittobo America is a company engaged in the manufacture of immunodiagnostic products.	BBI Solutions BBI Solutions is a company that develops and manufactures immuno-diagnostics reagents.
Founding Date	Founding Date N/A	Founding Date 1971	Founding Date 2013	Founding Date 1986	Founding Date 1986
Type	Type Private	Type Public	Type Subsidiary	Type Private	Type Private
Tags	Tags Healthcare Manufacturing & Industrial biotech medical diagnostics	Tags Healthcare Manufacturing & Industrial biotech medical diagnostics	Tags Healthcare Manufacturing & Industrial biotech medical diagnostics medtech	Tags Healthcare Manufacturing & Industrial biotech contractor medical diagnostics	Tags Healthcare biotech medical diagnostics
Locations	Locations Lake Clear, US HQ	Locations Irvine, US HQ	Locations Manchester, GB HQ	Locations Murrieta, US HQ	Locations Crumlin, GB HQ Freiburg Im Breisgau, DE Cape Town, ZA Edinburgh, GB Porton Down, GB Sittingbourne, GB see more
Employees	Employees N/A	Employees 39	Employees 1	Employees N/A	Employees 3491% increase
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) $5.3m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) £55.5m (FY, 2020)
Cost of goods	Cost of goods N/A	Cost of goods $4.8m (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods £25.4m (FY, 2020)
Gross profit	Gross profit N/A	Gross profit $498k (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit £30.1m (FY, 2020)
Net income	Net income N/A	Net income ($5m) (FY, 2025)	Net income N/A	Net income N/A	Net income (£9.9m) (FY, 2020)